| 학회 | 한국고분자학회 |
| 학술대회 | 2005년 봄 (04/14 ~ 04/15, 전경련회관) |
| 권호 | 30권 1호, p.91 |
| 발표분야 | 의료용 고분자 부문위원회 |
| 제목 | Functional hydrogels for the delivery of biological molecules |
| 초록 | The rapid development in cell biology and biotechnology makes a tendency producing more drugs based on proteins, peptides, and nucleic acids, which have short in vivo half-lives in many cases, so are more unstable and difficult to handle compared to the traditional synthetic, hydrophobic small molecular weight drugs. Therefore, new drug delivery systems for these biological drugs have been and are being developed. Hydrogels that have the high excluded volume are one of the good candidates since they can effectively protect the incorporated molecules from the surrounding biological environment, and generally show a minimal biocompatibility problem. Some examples of the functional hydrogels for the improved delivery of biological molecules including cells will be presented. 1) Hydrogel system can be obtained by controlling the self-assembly of telechelic polymers with hydrophilic midblocks (poly(ethyleneglycol), PEG) and hydrophobic end groups (fluoroalkyl, Rf) associating polymers. Disruption of the aggregation of the end groups using biocompatible complexing agents or solvents produces a low viscosity liquid that is injectible. Then, in situ formation of the gel once inside the body can be achieved gently by diffusion of the complexing agent or solvent out into the surrounding tissue. By modulating molecular structure, the mechanical and erosion properties of these hydrogels can be systematically varied over a wide range for desired applications including sustained release of therapeutic proteins. 2) An affinity-based controlled release system for growth factors having heparin-binding domains can be prepared using a crosslinked heparin gel by modifying carboxylic acid groups of heparin to react with activated bifunctional PEG. The release of loaded vascular endothelial growth factor (VEGF), a key factor in angiogenesis, from the hydrogel, measured by an ELISA assay, shows a slow, controlled release over 3 weeks with little initial burst. The released VEGF also maintains its biological activity, measured with a proliferation assay utilizing human umbilical vein endothelial cells (HUVEC). 3) By employing the biologically benign crosslinking chemistry, the in situ forming heparin-based hydrogel can be used as a cell encapsulating matrix. Cell encapsulation using this crosslinking strategy reveals that most of cells were alive during and after gellation, and cellular activities of several kinds of cells inside the hydrogel were also confirmed. |
| 저자 | 태기융 |
| 소속 | 광주과학기술원 |
| 키워드 | hydrogel; in situ forming; growth factor |
